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Abstract
Following EU Accession, Malta has to adopt EU Directives 
as part of its own legislation.  Three such directives concern the 
conduct of clinical trials in European countries – 2001/20/EC, 
2003/94/EC and 2005/28/EC.  These directives, and the 
respective guidelines explaining their implementation, have 
considerably changed the way clinical trials are conducted. 
While the participation of Malta in clinical trials is to be 
encouraged for various reasons, these have to be regulated 
according to the legislation set out by the European Union. 
In themselves, what these Directives strive to achieve are 
mainly the safety of the study subject and the protection of 
the investigators from serious consequences. This short article 
aims to give a brief overview of these changes to prospective 
investigators and hospital administrators.
Overview
Following Malta’s accession to the European Union, the 
directives and guidance documents published by the European 
Commission concerning research on human subjects were 
adopted locally.  
The legislation concerning clinical trials consists of Directive 
2001/20/EC1 (transposed as Clinical Trials Regulations, 20042), 
Directive 2003/94/EC3 (transposed as Good Manufacturing 
Practice in Respect of Medicinal and Investigational Medicinal 
Products for Human Use Regulations, 20044) and Directive 
2005/28/EC5 which come into force at the end of January 
2006.*
Directive 2001/20/EC1 and the Clinical Trials Regulations, 
20042 apply to all interventional trials (Phase I - IV) involving 
investigational medicinal products in the Community (including 
non-commercial ones) beginning on or after 1 May 2004. This 
legislation applies to both the public and private sector.  
According to article 2(a) of Directive 2001/20/EC1 and 
Regulation 3 of the Clinical Trials Regulations, 20042 a clinical 
trial is ‘any investigation in human subjects intended to 
discover or verify the  clinical,  pharmacological  and/or  other 
pharmacodynamic  effects  of one or more investigational 
medicinal  products, and/or  to identify  any adverse  reactions 
to one or more   investigational   medicinal   products  and/or 
to  study   absorption,  distribution, metabolism  and excretion 
of one  or  more  investigational  medicinal  products with the 
object of ascertaining their safety and/or efficacy.’   
Article 2(e) of Directive 2001/20/EC1 and Regulation 3 
of the Clinical Trials Regulations, 20042 define sponsor as an 
‘individual, company, institution or organization which takes 
responsibility for the initiation, management and/or financing 
of a clinical trial.’ In the case of academic investigator-led trial, 
the principal investigator is often the sponsor. In commercial 
trials, applications are usually handled by the pharmaceutical 
company or the clinical research organisation (CRO) that is 
heading the trial, rather than by the investigator. In academic 
research the application is usually handled by the researcher 
or his delegate. 
Companies, CROs or researchers applying to regulatory 
authorities for a clinical trial can download a clinical trial 
application form6 from the European Commission’s EudraCT 
database sponsor portal on: http://eudract.emea.eu.int/. 
This database contains information on all clinical trials being 
conducted in the Community from 1 May 2004. The database 
may be accessed by the competent authorities of the European 
Union member states, European Medicines Agency and 
European Commission.   
In order to conduct a clinical trial in Malta separate copies 
of the application form must be submitted to the Medicines 
Authority and to the Health Ethics Committee. The applications 
to the Medicines Authority and Health Ethics Committee may 
be submitted in parallel or sequentially, as the sponsor wishes. 
A clinical trial may only start if the Health Ethics Committee 
has issued a favourable opinion and the Licensing Authority 
has issued an authorisation. Following successful validation, 
applications are assessed within a time frame as stipulated 
in  Directive 2001/20/EC1 and the Clinical Trials regulations, 
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2004.2 As part of the assessment the Medicines Authority or 
the Health Ethics Committee may require further information 
or clarification and in the meantime there may be a clock stop 
until the applicant answers.  
Furthermore, substantial amendments to an approved 
application should be implemented only after being separately 
authorised by the Medicines Authority and / or Health Ethics 
Committee (depending on the nature of the amendment). 
Amendments are considered to be substantial when they 
fit into the criteria set out by the applicable guideline.7 An 
amendment application form8 has been published by the 
European Commission. The Medicines Authority and Health 
Ethics Committee should also be notified when a clinical trial has 
ended or is halted. An end of trial form9 has also been published 
by the European Commission. 
Directive 2001/20/EC1, Clinical Trials Regulations, 
20042 and the guidance documentation10,11 published by the 
European Commission also define pharmacovigilance aspects 
and responsibilities with respect to pre-marketing and post-
marketing clinical trials conducted within or outside the 
European Community. Reporting mechanisms and timeframes 
are also defined. Sponsors should also submit, on request as well 
as once a year throughout the clinical trial, a safety report to the 
Medicines Authority and the Health Ethics Committee. 
Medicines Authority
The European Commission has published a guidance 
document7 for the initial submission, amendments and end of 
trials. One should note that a number of documents need to 
be included with the application to allow assessment. These 
are listed in a guidance document7 published by the European 
Commission. The Medicines Authority has also published 
guidance notes12 so as to explain the procedures within the 
local context. The Authority recommends that the documents 
published by the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals 
for Human Use should also be followed, including the Guideline 
for Good Clinical Practice.13  
According to Directive 2001/20/EC1 and the Clinical 
Trials Regulations, 20042 the sponsor should send electronic 
reports concerning Suspected Unexpected Serious Adverse 
Reactions (SUSARs) to the European Medicines Agency 
(Eudravigilance clinical trials database, accessible on: http://
www.eudravigilance.org) and the Medicines Authority.  The 
Medicines Authority has also published guidance documents14-16 
to explain further these pharmacovigilance obligations.
Pharmacovigilance obligations also hold for clinical trials 
which have started before 1 May 2004. For this reason clinical 
trials which started before 1 May 2004 and are still ongoing 
need to be notified to the Medicines Authority. After 1 May 2004 
any new trial  needs to be approved as detailed above before it 
can commence. 
Health Ethics Committee
The ethics committee involved in the review of clinical trials 
in Malta as per the Clinical Trials Regulations, 20042 is the 
Health Ethics Committee, as established by the notice in the 
Malta Government Gazette of 29th April 2005.17  The members 
were appointed by the Director General (Health). The list of 
members of this Committee may be seen at the HEC website on 
www.sahha.gov.mt, under the heading ‘Statutory Bodies’. This 
Committee meets every month. 
Article 6(3) of Directive 2001/20/EC1 and Regulation 7(2) 
of the Clinical Trials Regulations, 20042 list the points which 
the Health Ethics Committee should consider when assessing 
an initial clinical trial submission:
‘In preparing its opinion, the Ethics Committee shall 
consider, in particular:
(a)  the relevance of the clinical trial and the trial design;
(b)  whether the evaluation of the anticipated benefits and 
risks is satisfactory and whether the conclusions are 
justified;
(c)  the protocol;
(d)  the suitability of the investigator and supporting staff;
(e)  the investigator’s brochure;
(f)  the quality of the facilities;
(g)  the adequacy and completeness of the written 
information to be given and the procedure to be followed 
for the purpose of obtaining informed consent and the 
justification for the research on persons incapable of 
giving informed consent;
(h) provision for indemnity or compensation in the event of 
injury or death attributable to a clinical trial;
(i)  any insurance or indemnity to cover the liability of the 
investigator and sponsor;
(j)  the amounts and, where appropriate, the arrangements 
for rewarding or compensating investigators and trial 
subjects and the relevant aspects of any agreement 
between the sponsor and the site;
(k)  the arrangements for the recruitment of subjects.’
The informed consent, patient information leaflet as well 
as any other documentation which has to be completed by the 
patient should be in both Maltese and English.
The European Commission has published a guidance 
document18 for the initial submission of documentation for 
an ethics committee opinion. One should note that a number 
of documents need to be included with the application to 
allow assessment. These are listed in this guidance document 
published by the European Commission. Additional information 
may be found in the guidance notes19 which were published 
by the Health Ethics Committee. Applications of substantial 
amendments together with notifications of SUSARs and 
terminations of clinical trials should also be sent to the Health 
Ethics Committee.
Any researchers planning studies not involving clinical trials 
are invited to submit their proposals to the Medical School 
Research Ethics Committee as is customary.
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Conclusion
The Health Ethics Committee and the Medicines Authority 
are well aware that these regulations may have radically changed 
the way that clinical trials are conducted in Malta.  Even 
though these regulations may be interpreted as an unwelcome 
imposition from the European Union, they have been instituted 
to protect both study participants and investigators from any 
unwelcome consequences that have caused deaths and ruined 
the reputation of some researchers in the past.   
As mentioned initially, these technicalities are usually 
tackled by the industry, that is pharmaceutical companies and 
CROs, that approach investigators with an invitation to join 
a clinical trial.  These companies are very familiar with the 
above procedures and are also aware that the requirements 
in Malta are similar to those of other European agencies and 
ethics committees.  Clinicians and health care professionals, as 
investigators or representatives of clinical trial centres, should 
be aware of these regulations so as to know the extent of their 
duties and responsibilities. 
The Medicines Authority and Health Ethics Committee did 
not add any requirements other than those requested by other 
European agencies.  Separate sets of documents are required 
for the two bodies to conduct separate assessments as expected 
by the legislation. These two bodies have to meet obligations 
and responsibilities. 
Investigators are invited to contact the Medicines Authority 
(prelicensing.mru@gov.mt) and/or the Health Ethics Committee 
(hec@gov.mt), should they require further advice.  The Health 
Ethics Committee also invites investigators to contact the 
Committee, preferably in writing, should they wish to discuss 
issues with the Committee during one of their meetings.
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